Hong Kong Stock News

MMG (SEHK:1208) just rolled out a sweeping leadership reshuffle, with CAO Liang taking over as chairman and new presidents appointed for Las Bambas and Africa. For investors, this is really about future strategy and execution. See our latest analysis for MMG. The shake up comes after a powerful run in the shares, with MMG’s 1 month share price return of 19.10% and 3 month share price return of 45.70% adding to an already substantial year to date share price return of 237.85%. The 1 year total...

At its extraordinary general meeting on 12 December 2025, AviChina Industry & Technology approved amendments to its Articles of Association, including abolishing the Supervisory Committee system, and confirmed the appointment of Mr. Gao Jiming as a non-executive director through 2027. This governance overhaul reduces one layer of oversight while reshaping the board, raising fresh questions about how management will now be monitored. We will now examine how the abolition of the Supervisory...

If you have been wondering whether Semiconductor Manufacturing International is still a smart buy after its huge run up, you are not alone. This stock has become a lightning rod for debates about value versus momentum. Despite a recent pullback of around 2.9% over the last week and 7.6% over the last month, the shares are still up an eye catching 133.4% year to date and about 161.4% over the past year, which naturally raises questions about how much upside might be left. These moves have...

If you are wondering whether Ascentage Pharma Group International is still a smart way to get exposure to biotech upside, you are not alone. That is exactly what we are going to unpack here. Despite a choppy recent stretch, with the share price down 6.8% over the last week and 8.1% over the past month, the stock is still sitting on gains of 35.4% year to date and 53.1% over the last year, building on a 131.9% return over three years. Recent moves have been shaped less by day to day trading...

In the past week, InnoCare Pharma reported China NMPA approval of zurletrectinib (ICP-723) for NTRK fusion-positive solid tumors in patients aged 12 and above, alongside strong efficacy and safety data, while also showcasing extensive positive clinical results for orelabrutinib and mesutoclax at the ASH 67th Annual Meeting. This marks InnoCare’s first approved solid-tumor therapy, adding a blood–brain-barrier-penetrant TRK inhibitor to its portfolio and underscoring its push to build a broad...

CStone Pharmaceuticals announced that its RET-targeted cancer therapy GAVRETO® (pralsetinib) has been approved for inclusion in China’s National Reimbursement Drug List, with reimbursement due to begin on 1 January 2026. This listing materially broadens patient access in China’s public healthcare system, potentially reinforcing CStone’s role as a key oncology player in Greater China. We’ll now examine how NRDL inclusion for GAVRETO shapes CStone’s investment narrative, particularly around...

If you are wondering whether BYD is still a smart buy at today’s price, or if the big gains are mostly behind it, this article will walk through what the current market is really pricing in. After a 14.4% gain year to date and a 46.5% climb over 3 years, the recent 2.0% pullback over the last month suggests sentiment is cooling a bit, but not necessarily the long term story. Investors have been reacting to a mix of headlines around global EV competition, shifting subsidies in China, and...

You may think that with a price-to-sales (or "P/S") ratio of 0.2x Enviro Energy International Holdings Limited...

Key Insights The considerable ownership by private equity firms in Xiamen Yan Palace Bird's Nest Industry indicates...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect...

From what we can see, insiders were net sellers in China Youran Dairy Group Limited's ( HKG:9858 ) during the past 12...

With a median price-to-sales (or "P/S") ratio of close to 0.8x in the Hospitality industry in Hong Kong, you could be...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

With a median price-to-sales (or "P/S") ratio of close to 0.5x in the Basic Materials industry in Hong Kong, you could...

YesAsia Holdings Limited's (HKG:2209) stock price has dropped 11% in the previous week, but insiders who sold US$5.0m...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

Shareholders appeared to be happy with DYNAM JAPAN HOLDINGS Co., Ltd.'s ( HKG:6889 ) solid earnings report last week...

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...

Key Insights Lai Fung Holdings' Annual General Meeting to take place on 19th of December Salary of HK$1.61m is part of...

Key Insights TBK & Sons Holdings will host its Annual General Meeting on 19th of December CEO Han Tan's total...

We'd be surprised if China International Development Corporation Limited ( HKG:264 ) shareholders haven't noticed that...

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

Soft earnings didn't appear to concern Man Wah Holdings Limited's ( HKG:1999 ) shareholders over the last week. Our...